Q1 2021 Financial Highlights: Total net revenue was $16.2 million, nearly all of which was software-related revenue Gross margin was...
Proven in oncology, the Eviti Connect payer solution expands to help reduce reimbursement inefficiencies and manage drug costs for disease...
Culver City, Calif. – May 4, 2021 — NantHealth, Inc. (NASDAQ-GS: NH), a provider of enterprise solutions that help businesses...
Transaction proceeds to be used to retire NantHealth’s existing convertible notes due in 2021, invest in established businesses, and accelerate...
NantHealth’s unified platform integrates multiple data sources so that payers and providers can proactively engage with patients and increase the...
Q4 Financial Highlights 2020 vs 2019: Total revenue was $18.6 million Total software-related revenue was $18.6 million, up from $18.4 million...
Culver City, Calif. – February 22, 2021 — NantHealth, Inc. (NASDAQ-GS: NH), a provider of enterprise solutions that help businesses...
New York, NY & El Segundo, CA – January 25, 2021: NantHealth, Inc. (NASDAQ: NH), a provider of enterprise solutions...
NantHealth’s study data shows: Adoption of trastuzumab biosimilars in treatment of HER2-positive breast cancer is significant; does not appear to...
Study demonstrates the viability and value of RNA sequencing from formalin fixed samples in gaining a deeper understanding of patient...
Q3 2020 Financial Highlights: Total net revenue was $18.8 million, up from $18.6 million Total software-related revenue increased to $18.7...
Culver City, Calif. – October 30, 2020 — NantHealth, Inc. (NASDAQ-GS: NH), a provider of enterprise solutions that help businesses...
